Remifentanil versus remifentanil/midazolam for ambulatory surgery during monitored anesthesia care. 1997

M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
University of Miami, Anesthesia Service, Veterans Administration Medical Center, Florida 33125, USA.

BACKGROUND This study was designed to define the appropriate dose of remifentanil hydrochloride alone or combined with midazolam to provide satisfactory comfort and maintain adequate respiration for a monitored anesthesia care setting. METHODS One hundred fifty-nine patients scheduled for outpatient surgery participated in this multicenter, double-blind study. Patients were randomly assigned to one of two groups: remifentanil, 1 microgram/kg, given over 30 s followed by a continuous infusion of 0.1 microgram.kg-1.min-1 (remifentanil), remifentanil, 0.5 microgram/kg, given over 30 s followed by a continuous infusion of 0.05 microgram.kg-1.min-1 (remifentanil+midazolam). Five minutes after the start of the infusion, patients received a loading dose of saline placebo (remifentanil) or midazolam, 1 mg, (remifentanil+midazolam). If patients were not oversedated, a second dose of placebo or midazolam, 1 mg, was given. Remifentanil was titrated (in increments of 50% from the initial rate) to limit patient discomfort or pain intraoperatively, and the infusion was terminated at the completion of skin closure. RESULTS At the time of the local anesthetic, most patients in the remifentanil and remifentanil+midazolam groups experienced no pain (66% and 60%, respectively) and no discomfort (66% and 65%, respectively). The final mean (+/-SD) remifentanil infusion rates were 0.12 +/- 0.05 microgram.kg-1.min-1 (remifentanil) and 0.07 +/- 0.03 microgram.kg-1.min-1 (remifentanil+midazolam). Fewer patients in the remifentanil+midazolam group experienced nauses compared with the remifentanil group (16% vs. 36%, respectively; P < 0.05). Four patients (5%) in the remifentanil group and two patients (2%) in the remifentanil+midazolam group experienced brief periods of oxygen desaturation (SpO2 < 90%) and hypoventilation (< 8 breaths/ min). CONCLUSIONS Remifentanil alone or combined with midazolam provided adequate analgesia and maintained adequate respiration at the doses reported. The low dose of remifentanil combined with 2 mg midazolam, compared with remifentanil alone, resulted in fewer side effects, slightly greater sedation, and less anxiety.

UI MeSH Term Description Entries
D008297 Male Males
D008874 Midazolam A short-acting hypnotic-sedative drug with anxiolytic and amnestic properties. It is used in dentistry, cardiac surgery, endoscopic procedures, as preanesthetic medication, and as an adjunct to local anesthesia. The short duration and cardiorespiratory stability makes it useful in poor-risk, elderly, and cardiac patients. It is water-soluble at pH less than 4 and lipid-soluble at physiological pH. Dormicum,Midazolam Hydrochloride,Midazolam Maleate,Ro 21-3981,Versed,Hydrochloride, Midazolam,Maleate, Midazolam,Ro 21 3981,Ro 213981
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010880 Piperidines A family of hexahydropyridines.
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077208 Remifentanil A piperidine-propionate derivative and opioid analgesic structurally related to FENTANYL. It functions as a short-acting MU OPIOID RECEPTOR agonist, and is used as an analgesic during induction or maintenance of general anesthesia, following surgery, during childbirth, and in mechanically ventilated patients under intensive care. 3-(4-Methoxycarbonyl-4-((1-oxopropyl)phenylamino)-1-piperidine)propanoic Acid Methyl Ester,GI 87084B,GI-87084B,GI87084B,Remifentanil Hydrochloride,Remifentanil Monohydrochloride,Ultiva
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000701 Analgesics, Opioid Compounds with activity like OPIATE ALKALOIDS, acting at OPIOID RECEPTORS. Properties include induction of ANALGESIA or NARCOSIS. Opioid,Opioid Analgesic,Opioid Analgesics,Opioids,Full Opioid Agonists,Opioid Full Agonists,Opioid Mixed Agonist-Antagonists,Opioid Partial Agonists,Partial Opioid Agonists,Agonist-Antagonists, Opioid Mixed,Agonists, Full Opioid,Agonists, Opioid Full,Agonists, Opioid Partial,Agonists, Partial Opioid,Analgesic, Opioid,Full Agonists, Opioid,Mixed Agonist-Antagonists, Opioid,Opioid Agonists, Full,Opioid Agonists, Partial,Opioid Mixed Agonist Antagonists,Partial Agonists, Opioid

Related Publications

M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
December 1996, Anesthesiology,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
August 2008, Journal of clinical anesthesia,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
July 2012, Korean journal of anesthesiology,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
January 2001, Anesthesia and analgesia,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
June 2003, European journal of anaesthesiology,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
November 2010, Journal of clinical anesthesia,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
April 2016, Journal of neurosurgical anesthesiology,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
May 2003, Journal of clinical anesthesia,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
March 1997, Journal of clinical anesthesia,
M I Gold, and W D Watkins, and Y F Sung, and J Yarmush, and F Chung, and N T Uy, and W Maurer, and M Y Clarke, and B D Jamerson
January 2004, Canadian journal of anaesthesia = Journal canadien d'anesthesie,
Copied contents to your clipboard!